 - From the projected start of scheduled study treatment, the following time periods must have elapsed: 5 half-lives from any investigational agent, 4 weeks from cytotoxic therapy except 23 days for temozolomide and 6 weeks from nitrosoureas, 6 weeks from antibodies, or 4 weeks or 5 half-lives, whichever is shorter from other anti-tumor therapies. 